Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare - Report - MDSpire

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • By

  • Junfeng Ma

  • Peng Yan

  • Chonghua Liu

  • Yuanyuan Wang

  • June 8, 2026

  • 0 min

Share

Clinical Report: Effective Surgical Intervention Following Chemotherapy in NSCLC

Overview

{'remove': ['the patient achieved a significant response and remains disease-free with a progression-free survival of 20 months']}

Background

{'remove': ['This case highlights the need for individualized treatment strategies in this complex patient population.']}

Data Highlights

ParameterValue
Age41 years
StageIVA (cT4N0M1a)
MutationEGFR exon 18 (E709_T710>del)
PD-L1 Expression55% (TPS)
Progression-Free Survival20 months

Key Findings

{'remove': ['Successful conversion surgery was performed after a strict preoperative bevacizumab washout period.']}

Clinical Implications

{'remove': ['It suggests that chemotherapy combined with antiangiogenic therapy may be a viable alternative to immunotherapy in this population.']}

Conclusion

{'remove': ['This case illustrates the complexities of treating advanced NSCLC in patients with active autoimmune diseases.']}

Related Resources & Content

  1. Frontiers in Oncology, 2026 -- Dynamic TKI combination strategies for EGFR-mutant NSCLC with acquired ROS1 fusion and brain metastases
  2. Frontiers in Oncology, 2026 -- Dramatic response to amivantamab plus chemotherapy in EGFR G719A–mutant lung adenocarcinoma with liver and peritoneal metastases
  3. The ASCO Post, 2022 -- Highlights From the ESMO Congress 2022
  4. The ASCO Post, 2025 -- Surgical Resection With EGFR TKI Demonstrates Promising PFS in EGFR-Mutant NSCLC
  5. Journal of Clinical Oncology, 2024 -- Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3
  6. Journal of Clinical Oncology, 2020 -- Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations.
  7. PubMed, 2024 -- First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial
  8. Therapy for Stage IV Non–Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3 | Journal of Clinical Oncology
  9. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. | Journal of Clinical Oncology
  10. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial - PubMed

Original Source(s)

Case Report: Successful conversion surgery following chemo-antiangiogenic therapy in a lung adenocarcinoma patient with active rheumatoid arthritis and rare EGFR mutation after immunotherapy-triggered flare

  • by Junfeng Ma, Peng Yan, Chonghua Liu, Yuanyuan Wang

  • June 8, 2026

Related Content

Lymphocyte CD4/CD8 ratio predicts early immune-related toxicity in lung cancer patients treated with immune checkpoint inhibitors: a single-center retrospective study

Editorial: Discovery of small molecule lead compounds: a driving force to unravel new anti-cancer targets and mechanisms, volume III

Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer